Neuroleptic malignant syndrome (NMS): risk factors
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Neuroleptic malignant syndrome (NMS): risk factors. Previous NMS, Parenteral administration, Higher doses. Fully referenced neurology checklist.
Neuroleptic-related risk factors
- Previous NMS
- Parenteral administration
- Higher doses
- Abrupt dose reduction
- Depot formulation
- Concomitant use of Lithium and SSRIs
Other risk factors
Locked: subscribe to see this section.
Acronym
Locked: subscribe to see this section.
References
- Munhoz RP, Moscovich M, Araujo PD, Tieve HAG. Movement disorders emergencies: a review. Arq Neuropsiquiatr 2012; 70:453-461.
- Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry 2007; 164:871-876.
- Nagamine T. Neuroleptic malignant syndrome associated with COVID-19 vaccination. CJEM 2022; 24:349-350.
